Clinical utility of risedronate in postmenopausal osteoporosis: patient considerations with delayed-release formulation.

Int J Womens Health · 2012 · PMC3333827 · PMID 22532780

Europe PMC DOI

hedged sentence

0.0040

closest p · 0.1× alpha

0.0040

boldest claim

The sentences

an observed trendP = 0.004actually significant

However, in comparing the 35 mg before breakfast and 35 mg after breakfast regimens, there was an observed trend for higher incidences of upper absorptiometry tract adverse effects ( P = 0.004).

also in 504 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.